SQZ Biotechnologies EBITDA 2020-2023 | SQZ

SQZ Biotechnologies ebitda from 2020 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
SQZ Biotechnologies Annual EBITDA
(Millions of US $)
2022 $-69
2021 $-58
2020 $-40
2019 $-31
SQZ Biotechnologies Quarterly EBITDA
(Millions of US $)
2023-03-31 $-15
2022-12-31 $-11
2022-09-30 $-20
2022-06-30 $-20
2022-03-31 $-18
2021-12-31 $-9
2021-09-30 $-20
2021-06-30 $-16
2021-03-31 $-13
2020-12-31 $-15
2020-09-30 $-10
2020-06-30 $-7
2020-03-31 $-8
2019-12-31
2019-09-30 $-8
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.018B $0.021B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $137.942B 8.43
GSK (GSK) United Kingdom $69.839B 9.75
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
QIAGEN (QGEN) Netherlands $10.584B 22.35
Ginkgo Bioworks Holdings (DNA) United States $3.379B 0.00
Arcus Biosciences (RCUS) United States $1.536B 0.00
Biohaven (BHVN) United States $1.482B 0.00
Emergent Biosolutions (EBS) United States $0.416B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.191B 0.00
Enzo Biochem (ENZ) United States $0.110B 0.00